Valitor
PrivateLast Round
Series B
Oct 5, 2022
Total Funding Raised
$28M
Company Overview
Valitor operates in Healthcare & Life Sciences and is based in Berkeley, California. Its latest recorded funding round was a Series B round in October 2022.
Valitor is a biotechnology company that develops long-acting therapeutic proteins using a proprietary multivalent biopolymer technology platform to improve treatment outcomes in ophthalmology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Valitor Comparables
Compare Valitor with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Serina Therapeutics Inc | 81% | |
| Day One Biopharmaceuticals | 76% | |
| Sanofi | 73% |
For institutional investors. Book with your work email.
Valitor Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 5, 2022 | ||||
| VC Round | Dec 22, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Valitor Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Berkeley Catalyst Fund | Series B, Series A |
| First Spark Ventures | Series B |
| Morningside Group | Series B |
| ExSight Ventures | Series B |
| Pandect Bioventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 3, 2026
Presenting new preclinical data at the ARVO Annual Meeting on May 3, 2026.
- Apr 13, 2026
CEO to present at the 25th Annual Needham Virtual Healthcare Conference.
For institutional investors. Book with your work email.
Valitor Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Valitor's valuation, stock price, and market status.
Is Valitor a public or private company?
Valitor is a private company.
What is the current stock price of Valitor?
Valitor is a private company, so its shares have no public market price. Caplight tracks Valitor's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Valitor worth (valuation)?
Valuation information for Valitor is not publicly available.
Can I buy Valitor stock?
Valitor shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Valitor's last funding round?
Valitor's most recent funding round was Series B on October 5, 2022.
Who are the main investors in Valitor?
Key investors in Valitor include Berkeley Catalyst Fund, Morningside Group, Pandect Bioventures.
Will Valitor IPO soon?
No public IPO plans have been announced for Valitor.
How can I track Valitor secondary market activity?
Caplight tracks bids, offers, and trades in Valitor's shares on secondary markets.